Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 35.6% in May

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 21,700 shares, an increase of 35.6% from the May 15th total of 16,000 shares. Based on an average daily volume of 82,500 shares, the short-interest ratio is currently 0.3 days. Currently, 0.9% of the company’s stock are short sold.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Armistice Capital LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned approximately 3.38% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by institutional investors and hedge funds.

Creative Medical Technology Trading Up 11.6%

Shares of NASDAQ CELZ opened at $2.50 on Thursday. The stock has a fifty day moving average price of $2.07 and a 200 day moving average price of $2.72. Creative Medical Technology has a 12-month low of $1.69 and a 12-month high of $6.90. The company has a market cap of $6.48 million, a P/E ratio of -0.66 and a beta of 1.98.

Creative Medical Technology (NASDAQ:CELZ) last issued its earnings results on Friday, May 9th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.31). The firm had revenue of $0.00 million during the quarter. On average, sell-side analysts forecast that Creative Medical Technology will post -3.19 EPS for the current fiscal year.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.